About The Rx Consultant

The Rx Consultant is a subscription-based service that delivers practical updates & reviews covering all the top-selling drugs and common health conditions. Our publications focus on the facts busy front-line pharmacists and other health care practitioners need to stay current, and provide it a streamlined, easy reading style.

Founded in 1991, The Rx Consultant has subscribers throughout the United States, Canada & The United Kingdom. For 27 years, pharmacists, nurse practitioners and pharmacy technicians have relied on The Rx Consultant for accurate, unbiased updates they can trust. We are completely independent of the pharmaceutical industry and has no commercial bias.

→ Visit The Rx Consultant

Rx Blog users - Save 40% on a subscription to
The Rx Consultant

Use Promo Code RXBLOG18

→ Subscribe Now

1-800-798-3353 rxmail@rxconsultant.com

New research suggests that there may be a small risk of new onset psychosis among teens and young adults with ADHD who are treated with stimulant medications. Using data from 2 insurance claims databases, researchers reviewed patients who were 13-25 years old with an ADHD diagnosis and taking prescription methylphenidate (n=110,923) or an amphetamine (n= 110,923). They identified those who also had a diagnosis for a psychotic episode with a prescription for an antipsychotic medication.

New-onset psychosis occurred in roughly 1 in 660 of the ADHD patients receiving prescription stimulants. The psychotic episodes included hallucinations, delusional disorder, and hearing voices. The risk differed among stimulants; 1 of every 486 amphetamine (eg, Adderall®, Vyvanse®) users developed psychosis, compared with 1 in 1,046 patients taking methylphenidate (eg, Ritalin®, Concerta®). Higher risks were linked with extended-release formulations and lisdexamfetamine.

Since the risk is low for patients who have been taking stimulants for a long time (and doing well on them), changing treatment is not advised. More importantly, patients with ADHD who are starting stimulants should be screened for a prior history or family history of bipolar or other psychiatric disorder, and possibly the use of cannabis. It may be best to avoid amphetamines in these patients.

• Moran L, et al. N Engl J Med. 2019;380:1128-38.

Share This